



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/022,276	12/14/2001	Gilles Gosselin	NOV 1000 CON1	1728

20786 7590 04/11/2002

KING & SPALDING  
191 PEACHTREE STREET, N.E.  
ATLANTA, GA 30303-1763

EXAMINER

CRANE, LAWRENCE E

ART UNIT	PAPER NUMBER
----------	--------------

1623

DATE MAILED: 04/11/2002

4

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No. <b>10/022,276</b>	Applicant(s) <b>Gosselin et al.</b>	
	Examiner <b>L. E. Crane</b>	Group Art Unit <b>1623</b>	

**- THE MAILING DATE of this communication appears on the cover sheet beneath the correspondence address -**

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE **--3--** MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be filed after six months from the date of this communication.
- If the prior for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty days will be considered timely.
- If NO period for reply is specified above, such period shall, by default, expire SIX (6) MONTHS from the date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 USC §133).

## Status

- ☒ Responsive to communication(s) filed on **-12/14/01 (amdt A) & 03/05/02 (IDS)-**.
- ☐ This action is **FINAL**.
- ☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

## Disposition of Claims

- ☒ Claims **--13-62--** are pending in the application. Claims **-1-12-** have been cancelled.
- Of the above claim(s) **--1--** is/are withdrawn from consideration.
- ☐ Claim(s) **--1--** is/are allowed.
- ☒ Claims **--13-62--** are rejected.
- ☐ Claim(s) **--1--** is/are objected to.
- ☐ Claim(s) **--1--** are subject to restriction or election requirement.

## Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☒ The proposed drawings, filed on **-12/14/01-** are ☒ approved ☐ disapproved.
- ☐ The drawing(s) filed on **-1-** is/are objected to by the Examiner.
- ☐ The specification is objected to by the Examiner.
- ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119(a)-(d)

- ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119 (a)-(d).
- ☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been received.
- ☐ received in Application No. (Series Code/Serial Number) **-1-**.
- ☐ received in the national stage application from the International Bureau (PCT Rule 17.2(a)).
- \* Certified copies not received: **-1-**.

## Attachment(s)

- |  |   |
|--|---|
| <input checked="" type="checkbox"/> Information Disclosure Statement(s), PTO-1449, Paper No(s). <u><b>--03--</b></u> | <input type="checkbox"/> Interview Summary, PTO-413                     |
| <input checked="" type="checkbox"/> Notice of Reference(s) Cited, PTO-892  | <input type="checkbox"/> Notice of Informal Patent Application, PTO-152 |
| <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review, PTO-948                                     | <input type="checkbox"/> Other: <u><b>-1-</b></u>                       |

U.S. Patent Trademark Office

## Office Action Summary

PTO-326 (Rev. 06/19/01)  
S. N. 10/022,276

Part of Paper No. **04**

Copy for ☒ **FILE** ☐ **APPLICANT**

Art Unit 1623

5        Claims 1-12 have been cancelled, no claims have been amended, and new claims 13-62 have been added as per the preliminary amendment filed December 14, 2001. An Information Disclosure Statement (IDS) received March 5, 2002 has been entered and the references supplied considered.

Claims 13-62 remain in the case.

The disclosure is objected to because of the following informalities:

10        In the disclosure the term "EC<sub>50</sub>" is used repeatedly and appears to refer to a kind of biological activity, but examiner could not find within the disclosure (or within medical texts/dictionary immediately available) where this term is explicitly defined. Unless already defined (please indicate location), applicant is respectfully requested to provide a definition of this term at its first appearance within the disclosure.

Appropriate correction is required.

15        Claims 16-17 and 40-62 are rejected under 35 U.S.C. §112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one of ordinary skill in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

20        Claims 16-17 and 40-62 are enabled for the compounds tested within the instant disclosure (L-dA, L-dG, L-dC, L-dU, L-thymidine & L-dI, and binary mixtures thereof), but the disclosure does not reasonably provide enablement for the administration of any other L-nucleoside/L-nucleoside prodrug or mixtures of an L-nucleoside/L-nucleoside prodrug

Art Unit 1623

with one or more other antiviral agent(s) to treat a mammal infected with hepatitis B virus.

5        Claims 13-14, 16-17 and 40-61 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

      In claims 16 (line 7), 17 (line 7), 42 (line 5) and 53 (line 5) the term "arabinofuranolyl" is a technical misspelling. Did applicant intend the term to read -- arabinofuranosyl -- ?

10        In claims 16 (line 4), 17 (line 4) and 40-61, last line, the term "its" is grammatically incorrect. Did applicant intend the term to read -- a --? Similarly the last line of claims 13-14 should read -- a pharmaceutically acceptable salt thereof --.

15        Claim 39 is objected to under 35 C.F.R. §1.75(c), as being in improper dependent form because a multiple dependent claim cannot depend from any other multiple dependent claim. See MPEP §608.01(n). Accordingly, the claim has not been further treated on the merits.

20        A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. §101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the same invention in this context, means an invention drawn to identical subject matter. *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422, F.2d 438, 164 USPQ  
25        619 (CCPA 1970).

Art Unit 1623

A statutory type (35 U.S.C. §101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based on 35 U.S.C. §101.

5        Claim 62 is provisionally rejected under 35 U.S.C. §101 as claiming the same invention as that of claims 1-27 of allowed copending Application No. 09/371,747.

This is a provisional double patenting rejection since the conflicting claims have not in fact been patented.

10        The non-statutory double patenting rejection, whether of the obviousness-type or non-obviousness-type, is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent. *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); *In re Van Ornam*, 686 F. 2d 937, 214 USPQ 761 (CCPA 1982); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir 1985); and *In re Goodman*, 29 USPQ 2d 2010 (Fed. Cir. 1993).

20        A timely filed terminal disclaimer in compliance with 37 C.F.R. § 1.321(b) and (c) may be used to overcome an actual or provisional rejection based on a non-statutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 C.F.R. §1.78(d).

25        Effective January 1, 1994, a registered attorney or agent or record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 C.F.R. §3.73(b).

Art Unit 1623

Claims 13-61 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-27 of copending Application No. 09/371,747. Although the conflicting claims are not identical, they are not patentably distinct from each other because the method of treatment and the alleged active ingredients are directed to substantially overlapping subject matter.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. §102 that form the basis for the rejections under this section made in this Office action:

"A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent."

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States."

Claims 13-62 are rejected under 35 U.S.C. §102(b) as being anticipated by Medivir Aktiebolag '248 (PTO-892 ref. M).

Applicant is referred to the method of treating claims at page 12, claims 10, 11 and 14 in particular.

The following is a quotation of 35 U.S.C. §103(a) which forms the basis for all obviousness rejections set forth in this Office action:

"A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject

Art Unit 1623

matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made."

5 Claims 13-62 are rejected under 35 U.S.C. §103(a) as being unpatentable over **Medivir Aktiebolag '248** (PTO-892 ref. M) in view of **von Janta-Lipinski et al.** (PTO-892 ref. U).

10 The instant claims are directed to the treatment of hepatitis B viral infections in mammals including humans by the administration of a  $\beta$ -L-2'-deoxynucleoside or prodrug thereof wherein the nucleoside is selected from the group consisting of  $\beta$ -L-dC,  $\beta$ -L-dT and  $\beta$ -L-dU.

**Medivir Aktiebolag '248** is described in a rejection supra.

15 **von Janta-Lipinski et al.** discloses that certain  $\beta$ -L-nucleotides and analogues thereof inhibit the activity of DNA polymerase derived from hepatitis B virus(HBV), a possible explanation of the activity of  $\beta$ -L-nucleosides/nucleotides against HBV infections.

The secondary reference supports the disclosure of the primary reference, namely that  $\beta$ -L-nucleosides and related enantiomeric analogues are active anti-retroviral agents which are active against HBV.

20 It would have been obvious to a person of ordinary skill in the art at the time the invention was made to administer pharmaceutical compositions containing  $\beta$ -L-nucleosides and related enantiomeric analogues to a host suffering from an HBV viral infection.

25 One having ordinary skill in the art would have been motivated to combine these references because both references are directed to enantiomerically related compounds and their activity against HBV infections in mammalian cells.

Art Unit 1623

Therefore, the instant claimed method of treating HBV by the administration of one or more  $\beta$ -L-2'-deoxynucleotides would have been obvious to one of ordinary skill in the art having the above cited reference before him at the time the invention was made.

5        This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. §103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under  
10    37 C.F.R. §1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. §103(c) and potential 35 U.S.C. §§102(f) or (g) prior art under 35 U.S.C. §103(a).

15        Papers related to this application may be submitted to Group 1600 via facsimile transmission(FAX). The transmission of such papers must conform with the notice published in the Official Gazette (1096 OG 30, November 15, 1989). The telephone numbers for the FAX machines operated by Group 1600 are (703) 308-4556 and 703-305-3592.

20        Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner L. E. Crane whose telephone number is 703-308-4639. The examiner can normally be reached between 9:30 AM and 5:00 PM, Monday through Friday.

25        If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Johann Richter, can be reached at (703)-308-4532.




Serial No. 10/022,276

8

Art Unit 1623

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is 703-308-1235.

5 LECrane:lec  
04/10/02



L. Eric Crane  
Patent Examiner  
Group 1600